Medication & Safety
Return and Refund Policy: What to Check Before You Buy
A clear return and refund policy tells you a lot about a seller before anything goes wrong. Here is what to check before...
Semaglutide outperformed dulaglutide on both blood sugar and weight loss when the two were compared directly. That result came from a properly designed head-to-head trial, which makes it far more reliable than the cross-trial comparisons usually quoted online.
Both drugs are weekly injections for type 2 diabetes. Both belong to the GLP-1 class. The differences show up in how much they do, and in how they feel to use.
What each one is
Trulicity is dulaglutide, made by Eli Lilly, injected once weekly at 0.75 mg, 1.5 mg, 3.0 mg or 4.5 mg.
Ozempic is semaglutide, made by Novo Nordisk, injected once weekly at 0.5 mg, 1.0 mg or 2.0 mg.
Both are approved for type 2 diabetes. Neither is approved for weight loss. Weight loss occurs with both as a secondary effect of appetite reduction, but that is not their licensed purpose.
Both mimic GLP-1 (glucagon-like peptide-1, a hormone your gut releases after eating that signals fullness and helps regulate blood sugar).
The head-to-head trial
SUSTAIN 7, published in Lancet Diabetes and Endocrinology in 2018, compared the two drugs directly in people with type 2 diabetes over 40 weeks.
The weight results were clear.
| Comparison | Semaglutide | Dulaglutide | Difference |
|---|---|---|---|
| Low dose | 4.6 kg | 2.3 kg | 2.26 kg |
| High dose | 6.5 kg | 3.0 kg | 3.55 kg |
Semaglutide 1.0 mg produced 6.5 kg of weight loss. Dulaglutide 1.5 mg produced 3.0 kg. That is roughly double.
Blood sugar control followed the same pattern. The trial concluded semaglutide was superior to dulaglutide for both glycaemic control and body weight reduction, with both differences highly statistically significant.
One caveat worth stating. SUSTAIN 7 compared dulaglutide at 0.75 mg and 1.5 mg. Trulicity's higher doses of 3.0 mg and 4.5 mg were approved later and were not part of this comparison. Those higher doses narrow the gap somewhat, though they do not close it.
Ease of use
This is where Trulicity has a genuine advantage.
The Trulicity pen comes pre-attached with a hidden needle. You do not attach a needle, you do not see it, and you do not dial a dose. You press it against your skin and push a button.
For people who are needle-averse, this matters considerably. It is a meaningfully less intimidating device.
Ozempic requires attaching a needle to the pen and dialling the dose. It is not difficult, but it involves more handling and more visible needle.
Both are once weekly, so injection frequency is identical.
Dose escalation
Trulicity starts at 0.75 mg weekly and can increase to 1.5 mg after four weeks, then further if needed.
Ozempic starts at 0.25 mg for four weeks, then 0.5 mg for at least four weeks, then 1.0 mg. Reaching the top dose takes eight to sixteen weeks.
Trulicity reaches a therapeutic dose faster. Ozempic escalates more slowly, which generally means better tolerability during the build-up but a longer wait for full effect.
Side effects
Both produce the same category of effects, because both slow gastric emptying.
Nausea, diarrhoea, vomiting and constipation lead the list for both drugs. In SUSTAIN 7, gastrointestinal side effects were common with both, and semaglutide had somewhat more of them at comparable points, which is consistent with its stronger effect.
There is a general pattern across this drug class. More weight loss and more blood sugar lowering usually come with more gastrointestinal disturbance. The two travel together.
Serious risks are shared. Pancreatitis, gallbladder disease and the medullary thyroid carcinoma contraindication apply to both. Neither is used in type 1 diabetes or during pregnancy.
Cardiovascular evidence
Both have cardiovascular outcome data, which matters for people with type 2 diabetes at elevated risk.
Semaglutide's cardiovascular evidence in diabetes comes from SUSTAIN-6. Dulaglutide's comes from the REWIND trial. Both demonstrated reductions in major adverse cardiovascular events in their respective populations.
This is a genuine tie. Neither has a clear cardiovascular advantage over the other, and either is a reasonable choice on that basis.
Which should you choose
Semaglutide if you want maximum blood sugar lowering and maximum weight effect, and you can tolerate somewhat more gastrointestinal disturbance.
Dulaglutide if needle anxiety is a real barrier for you, if you want a simpler device, or if you have tolerated semaglutide poorly. The easier pen is not a trivial factor. A drug you will actually inject weekly beats a stronger drug you avoid.
Neither for weight loss alone. Both are diabetes medications. If weight loss is the goal and you do not have diabetes, using either off-label means taking a drug at a dose not designed for that purpose.
Availability in Pakistan
Neither Trulicity nor Ozempic is registered in Pakistan. Both arrive through import channels, both need refrigeration, and both are priced against the dollar with the volatility that implies.
Semaglutide has faced repeated global supply shortages driven by weight loss demand, which has at times made it harder to obtain than dulaglutide even where both are imported.
For diabetes management, this is a serious problem and needs solving with your treating physician, not worked around independently.
For weight management specifically, the question is different. Neither drug was designed for that use, and neither can be relied on for continuous supply here. Doctor-guided weight loss drops in Pakistan exist precisely because that gap left most people with no supervised option at all. METASLIM™ is a physician-reviewed GLP-1 sublingual supplement, not a pharmaceutical GLP-1 receptor agonist, and it does not treat diabetes or replace any prescribed medication. It addresses appetite through the same pathway, with physician review built in.
To understand what that pathway actually does, our page on the mechanism behind GLP-1 support explains it in plain terms. Our guide to Saxenda covers the daily injectable option, and what a GLP-1 receptor agonist is covers the class.
The verdict
Semaglutide is the stronger drug. SUSTAIN 7 showed roughly double the weight loss and better blood sugar control than dulaglutide at the doses compared.
Trulicity is the easier drug to use, and for some people that decides it.
Both are diabetes medications first. Anyone considering either purely for weight loss should understand they are choosing an off-label use of a drug that requires a prescription, refrigeration and a supply chain that does not reliably exist in Pakistan.
Review the full program details if you want a structured, locally available option to compare against.
This article is for informational purposes only and does not constitute medical advice. Consult a qualified physician before starting any weight loss program, medication, or supplement.